Lung Cancer

Article	Citations
Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer	93
HLA-I levels correlate with survival outcomes in response to immune checkpoint inhibitors in non-small cell lung cancer	83
A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer	81
Comparative effectiveness of second-line immune checkpoint inhibitor therapy versus chemotherapy for malignant pleural mesothelioma	56
Clinical implementation of value based healthcare: Impact on outcomes for lung cancer patients	56
Surgical or medical strategy for locally-advanced, stage IIIA/B-N2 non-small cell lung cancer: Reproducibility of decision-making at a multidisciplinary tumor board	56
Mutant forms of EGFR promote HER2 trafficking through efficient formation of HER2-EGFR heterodimers	53
HALT: targeted therapy with or without dose-intensified radiotherapy in oligo-progressive disease in oncogene addicted lung tumours	49
Stereotactic ablative radiotherapy (SABR) for primary lung malignancy: a regional analysis of survival and recurrence outcomes amongst an elderly cohort	48
Sarcopenia is not a useful prognostic biomarker in metastatic NSCLC patients treated with first-line pembrolizumab	48
Clinical score for colorectal cancer patients with lung-limited metastases undergoing surgical resection: Meta-Lung Score	48
Real-world use of nivolumab plus ipilimumab in the management of diffuse pleural mesothelioma (DPM): experience from the county of Kent	46
Mobocertinib in previously treated patients with EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): updated results from a phase 1/2 study	45
Does consolidation radiotherapy to chest improve survival in extensive stage small cell lung cancer in the immunotherapy era? A retrospective study	44
Direct to CT screening pilot for patients with COPD in a deprived area: longitudinal analysis of the pulmonary nodule cohort outcomes	43
Prediction of next generation sequencing test failure in lung adenocarcinoma in a genomic laboratory hub setting	41
The role of mediastinoscopy following EBUS	40
Spatial microenvironment heterogeneity in therapy-naïve lung cancer: A concept with more attention needed	40
Two cases of non-small cell lung cancer patients with somatic or germline EGFR R776H mutation	40
Retrospective review of patterns of recurrence in patients with a histological diagnosis of thymoma	40
Indwelling pleural catheter infections: a cautionary tale	39
Author index	39
Antimuscarinics and lung cancer survival: A Norwegian population-based cohort study	38
Clinical relevance of circulating activin A and follistatin in small cell lung cancer	37
Randomized controlled clinical trial is needed for toxicity of IMRT VS 3D-CRT in PORT for LA-NSCLC	37

Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry	36
Phase 1 multicenter study of the HSP90 inhibitor SNX-5422 plus carboplatin and paclitaxel in patients with lung cancers	35
The first historical description of malignant mesotheliomas	35
Incorporating circulating tumor DNA detection to radiographic assessment for treatment response in advanced EGFR-mutant lung cancer	33
Proposal of a revised International Association for the Study of Lung Cancer grading system in pulmonary non-mucinous adenocarcinoma: The importance of the lepidic proportion	33
Putative mechanisms of primary resistance to EGFR-targeted therapies: A retrospective study	33
175 External Validation of a Left Anterior Descending Coronary Artery Dose Constraint in Patients with Non-Small Cell Lung Cancer: An NI–HEART Analysis	32
190 Localised non-small cell lung cancer: patient characteristics and radical radiotherapy outcomes according to KRAS mutation status	32
101 Treating advanced EGFR positive non-small cell lung cancer patients with Osimertinib - the University Hospital Plymouth experience	31
74 The first-in-class PRX3 inhibitor RSO-021 modulates the composition of malignant pleural effusions by eliciting immunomodulation and decreasing epithelial to mesenchymal protein expression	30
98 Hospitalisation Rates following Systemic Anti-Cancer Treatments for Patients with Non-Small Cell Lung Cancer	30
107 Osimertinib Efficacy in Advanced NSCLC Patients with PACC and Classical-Like EGFR Mutations: A Retrospective Analysis from The Christie	30
Title Page	29
260 Second Primary Lung Cancer Cohort Study (SPORT)	29
89 Why do almost half of our patients not complete 12 months of maintenance durvalumab after successful radical chemoradiotherapy?	29
251 Optimising engagement and addressing inequalities for patients using a Digital Behaviour Change Intervention in lung cancer prehabilitation: A mixed-methods study	29
86 Real World Outcomes of Patients Receiving Neoadjuvant Treatment for Non-Small Cell Lung Cancer	29
123 Using Prescribing Data to Estimate the Number of ALKpositive Patients Currently Living in England	28
108 Evaluation of a Lung Cancer Nurse led clinic for the routine follow up of uncomplicated post resection lung cancer patients	28
190 Decision Making for Thoracic Radiotherapy and Prophylactic Cranial Irradiation in ES-SCLC Post Chemoimmunotherapy	28
Frailty, comorbidity and cardiovascular risk assessment in older patients with lung cancer	27
APOBEC mutagenesis and selection for NFE2L2 contribute to the origin of lung squamous-cell carcinoma	27
Contents	27
Functional resilience and overall survival in adults treated for advanced non-small-cell lung cancer	27
Imaging in pleural mesothelioma: A review of the 15th International Conference of the International Mesothelioma Interest Group	27
Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the	27
Cell pellet from fixative medium of transbronchial lung biopsy sample improves lung cancer ancillary test	26
Evaluating lung cancer risk factors in adults with interstitial lung disease	25
Immune landscape and novel therapeutic targets of epidermal growth factor receptor and anaplastic lymphoma kinase wild type never-smoker lung adenocarcinoma	25
Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial	25
WHO histological classification and tumor size are predictors of the locally aggressive behavior of thymic epithelial tumors	24
Dynamic cytokines signature predicts survival outcome from severe Immune-related hepatitis with PD-1/PD-L1 blockade in lung cancer	24
Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide	24
Correlations between objective response rate and survival-based endpoints in first-line advanced non-small cell lung Cancer: A systematic review and meta-analysis	24
Response and acquired resistance to MET inhibitors in de novo MET fusion-positive advanced non-small cell lung cancer	24
A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival	24
Exploration on the first-line treatment of ERBB2-altered advanced non-small cell lung cancer: A multicenter retrospective study	24
A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9–15 PROMISE-meso phase III trial	24
Beyond environmental risk: Genetic insights into lung cancer susceptibility through whole exome analysis	23
Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study	23
219 “Fewer than 100 cigarettes in lifetime” deemed low risk for lung cancer – should we continue to offer Lung cancer screening to this cohort	22
206 Screening benefits and harms; a review of false positives and negatives from the Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Targeted Lung Health Check (TLHC) programme	22
Frozen sections accurately predict the IASLC proposed grading system and prognosis in patients with invasive lung adenocarcinomas	22
Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial	22
143 Comparative Evaluation of Clinical Frailty Scale and WHO Performance Status For Predicting 90-day and One-year Mortality in People with Lung Cancer	22
195 The impact of measured versus estimated height and weight on lung cancer screening eligibility – analysis from the Yorkshire Lung Screening Trial	22
Feasibility of salvage resection following locoregional failure after chemoradiotherapy and consolidation durvalumab for unresectable stage III non-small cell lung cancer	21
22 Challenges in Meeting Molecular Testing Turnaround Times in Lung Cancer	21
Clinical application of the Lung Cancer Compact PanelTM using various types of cytological specimens in patients with lung cancer	21
Clinicopathologic and genomic features of high-grade pattern and their subclasses in lung adenocarcinoma	21

A combined model of circulating tumor DNA methylated SHOX2/SCT/HOXA7 and clinical features facilitates the discrimination of malignant from benign pulmonary nodules	21
37 Diagnostic performance across two high-volume EBUS services in Greater Manchester with and without Rapid On-Site Evaluation (ROSE)	21
Treatment patterns and outcomes in early-stage ALK-rearranged non-small cell lung cancer	20
Effect of adherence to treatment guidelines on overall survival in elderly non-small-cell lung cancer patients	20
Modulating the gut microbiome in non-small cell lung cancer: Challenges and opportunities	20
Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for advanced nonsquamous non-small cell lung cancer with impaired renal function: A multicenter, single-arm phase 2 trial (RESTART	20
Artificial intelligence-based recurrence prediction outperforms classical histopathological methods in pulmonary adenocarcinoma biopsies	20
Leptomeningeal metastases in non-small cell lung cancer: Diagnosis and treatment	20
Analyzing diagnostic and treatment wait times for lung cancer Patients: Key insights from a provincial registry study	20
Contents	19
Can PDL-1 levels predict response to triple regimen (carboplatin + pembrolizumab+ pemetrexed) in treatment for metastatic non-small cell lung cancer – a real world outcome study	19
Contents	19
Contents	19
Complications after lung ablation: when can patients be safely discharged?	19
Real world prospective data on tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor mutation positive non-small cell lung cancer at the Edinburgh Cancer Centre	19
Contents	19
Contents	19
Survival outcomes following concomitant chemoradiation (CRT) for stage III non-small cell lung cancer (NSCLC) at Oxford University Hospitals (OUH) NHS Trust	19
Improving the use of NOACS for cancer-related VTE in Great Western Hospital	18
The impact of real-world lung cancer screening programmes on downstream diagnostic capacity	18
Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial	18
A District General Hospital (DGH) EBUS Service: a different model	18
Initial experience of CT guided percutaneous microwave ablation of lung metastasis in a district general hospital	18
Two years on: progression free survival analysis of patients with advanced small cell lung cancer receiving atezolizumab plus etoposide and carboplatin in a tertiary oncology centre	18
Audit of cyclophosphamide/adriamycin/vincristine (CAV) chemotherapy use in Edinburgh Cancer Centre	18
Lung cancer detection in the expanded Manchester Lung Health Check programme	18
Assessing the impact of the pharmacist independent prescriber as part of the multi-disciplinary care of patients receiving adjuvant treatment for NSCLC	18
Impact and causes of readmission within 90-days of non-small cell lung cancer surgery	18
Rethinking continuity in primary care for people with mesothelioma	18
Are robotic pulmonary lobectomies associated with as good nodal assessment as conventional surgery?	18
Contents	18
Crucial, complex, caring: a new professional development framework for Lung Cancer Nurse Specialists	17
Real-world dosage, tolerability and clinical outcomes in patients with squamous NSCLC treated with carboplatin, paclitaxel and pembrolizumab in the West of Scotland	17
67 The mental health and well-being implications of a mesothelioma diagnosis: a mixed methods study	17
204 REFINE-Lung is a multicentre phase III study to determine the optimal frequency of pembrolizumab in advanced non-small cell lung cancer (NSCLC) utilising a novel multi-arm design	17
Impact of introducing intensity modulated radiotherapy (IMRT) on curative intent radiotherapy and survival for lung cancer	17
69 New research-based resources to facilitate engagement with palliative care for patients and families living with mesothelioma	17
60 First-line Nivolumab/Ipilimumab in patients with unresectable malignant pleural Mesothelioma (MPM): West of Scotland experience	17
11 Making an accurate diagnosis of anterior mediastinal lesions: A proposal for a new diagnostic algorithm from the BTOG Thymic Interest Group	17
Malignant pleural mesothelioma: Comparison of surgery-based trimodality therapy to medical therapy at two tertiary academic institutions	17
31 The Nodules of Norfolk, Setting up a Pulmonary Nodule Pathway in a secondary care setting at the Norfolk & Norwich University Hospital – A reflective study over one year from January 2023 – Jan	17
135 The Impact of the Electronic Patient Record on Completion and Uploading of the Holistic Needs Assessment in Lung Cancer patients	17
109 Alk-positive NSCLC: Side effects - the real-world experiences of UK patients	16
56 High Frequency Jet Ventilation assisted CT guided lung biopsy service in a district general hospital	16
Evaluation of disease staging and chemotherapeutic response in non-small cell lung cancer from patient tumor-derived metabolomic data	16
Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure	16
173 Real world outcomes for patients receiving radical radiotherapy for stage 3 Non-Small Cell Lung Cancer post-PACIFIC	16
70 Trial protocol and update for the DREM study	16
95 Lorlatinib in advanced ALK-rearranged NSCLC – real-world experience in a UK population	16
Mutational analysis of pulmonary large cell neuroendocrine carcinoma: APC gene mutations identify a good prognostic factor	16
198 Pilot lung screening in Scotland: intervention findings and qualitative insights	16
193 The Impact of a Targeted Lung Health Check Program on Oncology Services at UHCW	16
93 A regional-West Midlands audit on implementing the neo-adjuvant chemoimmunotherapy (NACIO) pathway for resectable non-small cell Cancer (NSCLC) patients	16
Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP)	16
Predictive value and molecular correlates of MYC immunohistochemistry and copy number gain in non-small cell lung carcinomas treated with immunotherapy	16
Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison	15
Combination therapy with anti-programmed cell death 1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation	15
Immunogenicity of COVID-19 vaccines in lung cancer patients	15
Mutational landscape of primary pulmonary salivary gland-type tumors through targeted next-generation sequencing	15
A machine learning approach using clinical data for recurrence risk-stratification following radiotherapy for non-small cell lung cancer	15
Contents	15
Environmental asbestos exposure and lung cancer	15
Integration of on-treatment modified Glasgow prognostic score (mGPS) to improve imaging-based prediction of outcomes in patients with non-small cell lung cancer on immune checkpoint inhibition	15
FDG-PET/CT for pretherapeutic lymph node staging in non-small cell lung cancer: A tailored approach to the ESTS/ESMO guideline workflow	15
Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer	15
A case of lymphoepithelial carcinoma of the lung responding to treatment with pembrolizumab, paclitaxel and carboplatin	15
Two different patients with pulmonary pleomorphic carcinoma response to PD-1 inhibitor plus anlotinib	15
Commentary on: Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learning	15
Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions	15
Prognostic impact of adjuvant therapy for cisplatin-unfit patients with non-small-cell lung cancer: A multicenter analysis	15
Spatiotemporal distribution of mediastinal neoplasms: A comprehensive multi-center study	15
Construction and validation of a clinical differentiation model between peripheral lung cancer and solitary pulmonary tuberculosis	15
Vertebral compression fractures (VCF) an important risk factor in concurrent chemoradiotherapy (CRT) of stage II/ III lung cancer	14
Evaluation of diagnostic algorithms for initial lung cancer investigation: are bundles safe and efficient?	14
Endobronchial ultrasound–transbronchial nodal aspiration (EBUS-TBNA) with rapid on-site evaluation (ROSE) in the Ulster Hospital, 2021	14
BLU-701 tumour suppression and intracranial activity as a single agent and in combination with BLU-945 in models of non-small cell lung cancer (NSCLC) driven by EGFR mutations	14
Unradical Surgery for Locally-Advanced Thymoma: Is it time to evolve Perspectives?	14
Lung adenocarcinoma (LAC) with MET exon 14 skipping mutation treated with tepotinib: a case report	14
Optimisation of the treatment pathway for stage III non-small cell cancer (NSCLC) patients receiving concurrent chemo-radiation (cCRT)	14
Treatment dose-delay due to an exercise induced creatinine kinase level elevation/raise in a man with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (aNSCLC) – a case re	14

The clinical utility of Guardant360 in directing management of NSCLC patients – a small cohort study	14
The survival outcomes of patients with lung cancer managed as best supportive care	14
Drastic response of sunitinib after failure of Lenvatinib in patients with previously treated thymic carcinoma	14
Editorial Board	14
Contents	14
Patient and physician opinion of virtual care in the oncology department of an Irish tertiary care centre in the era of Covid-19	13
Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMS	13
Research on the road: taking lung cancer research to the patient	13
Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer	13
ALK rearrangement is an independent predictive factor of unexpected nodal metastasis after surgery in early stage, clinical node negative lung adenocarcinoma	13
The impact of the COVID-19 pandemic on pleural activity at Plymouth NHS Trust	13
Lymph Node Dissection in Thymoma: Is it worth it?	13
Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment	13
Heavy mutagenesis by tobacco leads to lung adenocarcinoma tumors with KRAS G12 mutations other than G12D, leading KRAS G12D tumors—on average—to exhibit a lower mutation burden	13
The future in the instant: The lung adenocarcinoma classification as a predictor of future adverse events	13
Understanding the mental health and well-being impacts and interventions related to living with mesothelioma: a systematic review	13
The effect of COVID-19 on the presentation, staging, and treatment of lung cancer: a retrospective comparative audit of the ‘first wave’	13
Corrigendum to “Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma – Interpretation guidance derived from two randomized EORTC trial	13
Prediction of prognosis in lung cancer using machine learning with inter-institutional generalizability: A multicenter cohort study (WJOG15121L: REAL-WIND)	13
Quantification of HER family dimers by proximity ligation assay and its clinical evaluation in non–small cell lung cancer patients treated with osimertinib	13
A problem with clinical T factor in the 8th TNM edition: Prognosis and EGFR mutation status of small sized lung cancers with difficulty to measure the diameter of solid component in part-solid tumor	13
Predicting checkpoint inhibitors pneumonitis in non-small cell lung cancer using a dynamic online hypertension nomogram	13
Perceived barriers to curative treatment for patients with early stage lung cancer: a mixed methods study	13
169 Can reminders improve lung cancer screening uptake amongst higher-risk populations?	12
Difference in efficacy of osimertinib between patients with EGFR-positive NSCLC with postoperative recurrence and those with de novo unresectable disease: A prospective, observational study	12
Adherence to community-based lung cancer screening in the Yorkshire Lung Screening Trial	12
54 A population-based review of early-onset lung cancer patients in Northern Ireland	12
Clinical significance of inter-assay discrepancy in PD-L1 evaluation for the efficacy of pembrolizumab in advanced NSCLC with high PD-L1 expression	12
46 Automated Derivation of Diagnostic Criteria for Lung Cancer using Natural Language Processing on Electronic Health Records: A pilot study	12
Comprehensive molecular profiling of squamous non-small cell lung cancer reveals high incidence of actionable genomic alterations among patients with no history of smoking	12
The modification of T description according to visceral pleural invasion and tumor size from 3.1 cm to 4.0 cm in non-small cell lung cancer: A retrospective analysis based on the SEER database	12
77 Toxicity and outcomes for patients with resected Non-Small cell lung cancer (NSCLC) who have received adjuvant chemotherapy in Bristol	12
Use of radiation therapy among patients with Extensive-stage Small-cell lung cancer receiving Immunotherapy: Canadian consensus recommendations	12
Efficacy and surgical safety of sequential surgical resection after pembrolizumab plus chemotherapy for initial unresectable stage IIIB non-small cell lung cancer	12
Asbestos-Related lung Cancer: An underappreciated oncological issue	12
157 Establishing a multidisciplinary habilitation clinic for lung cancer patients receiving radical radiotherapy	12
128 90 day admissions and mortality in lung cancer patients	12
Investigation on the survival implications of PD-L1 expression status in ALK- rearranged advanced non-small cell lung cancer treated with first-line crizotinib	12
PD-L1 assessment in cytology samples predicts treatment response to checkpoint inhibitors in NSCLC	12
Analyses of real-world data on patient outcomes in South Yorkshire, for patients with metastatic non-squamous lung cancer treated with pembrolizumab plus pemetrexed-platinum-based chemotherapy	11
Hamlet.rt Trans: a prospective single-centre translational sub-study evaluation of liquid biomarkers of radiation response	11
EBUS audit: assessing the diagnostic performance of the service at UHL	11
174 The prevalence and clinical outcomes of incidental thymic lesions detected through Lung Cancer Screening	11
Event-free survival (EFS) with neoadjuvant nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) versus chemo by surgical outcomes in resectable non-small cell lung cancer (NSCLC) from CheckMate 81	11
A reply to “managing oligoprogressive malignant pleural mesothelioma with stereotactic body radiation therapy”	11
Outcome of stereotactic ablative radiotherapy (SABR) in early stage non-small cell lung cancer (NSCLC)	11
PRIMALung (EORTC-1901-LCG): prophylactic cerebral irradiation or active brain magnetic resonance imaging surveillance in small-cell lung cancer patients	11
SYSTEMS-2: a randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma	11
10 years clinical outcome of TKIs in EGFR-mutant advanced NSCLC – UHNM experience	11
Lung cancer caused by asbestos: What a reporting pathologist needs to know	11
Editorial Board	11
Developing a framework for a telephone pathway for lung cancer patients receiving SACT	11
Real world experience of hypofractionated radical radiotherapy for non-small cell lung cancer (NSCLC) during the COVID-19 pandemic: a well-tolerated radiotherapy schedule with acceptable progression-f	11
The issue of no tissue: lung cancer patients without a tissue diagnosis in NHS Lothian	11
Implementing adjuvant immunotherapy following radical chemoradiotherapy for stage III non-small cell lung cancer in UK clinical practice: are the PACIFIC trial outcomes achievable in the real world?	11
118 Occupational causes of respiratory cancers: Current and emerging trends and promoting prevention	11
Lung cancer-associated T cell repertoire as potential biomarker for early detection of stage I lung cancer	11
Impact of perioperative fluids on clinical outcomes following thoracic surgery: a single-centre propensity matched retrospective study	11
Long response to immune checkpoint inhibitors in metastatic NSCLC despite EGFR germline mutation. A case report	10
USO1 in non-small cell lung cancer	10
Heterogeneity of PD-L1 expression in lung adenocarcinoma metastasis is related to histopathological subtypes	10
Corrigendum to “The emerging role of the lung microbiome and its importance in non-small cell lung cancer diagnosis and treatment” [Lung Cancer 165C (2022) 124–132]	10
Patient-Reported Distress and Clinical Outcomes with Immuno-Oncology Agents in Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Real-World Retrospective Cohort Study	10
Association between surgical quality and long-term survival in lung cancer	10
132 A review of why patients with performance status 0-2 didn't receive anti-cancer treatment	10
Pulmonary blastoma is successfully treated with immunotherapy and targeted therapy	10
Contents	10
18 The impact of radiology reporting delays on lung cancer care: A single centre experience	10
Improving community lung cancer follow-up strategies in South Greater Glasgow and Clyde using 1-year survival data	10
Adjuvant immunotherapy after concurrent chemoradiation for locally advanced NSCLC: audit from Northern Ireland	10
Type of lymphadenectomy does not influence survival in pIa NSCLC patients who underwent VATS lobectomy: Results from the national VATS group database	10
114 The role of the Patient Cancer Care Coordinator in the Lung Cancer Pathway – reducing health inequalities and optimising patient access	10
Anti–cytotoxic T-lymphocyte–associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small	10
Considerable interlaboratory variation in PD-L1 positivity in a nationwide cohort of non-small cell lung cancer patients	10
86 Does entering clinical trials achieve better survival outcomes compared to standard of care in metastatic non-small cell lung cancer patients	10
Geographic variation in delay to surgical treatment among non-small cell lung cancer patients	10
9 Evaluating outcomes in a district general hospital pleural service	10
A comparison of patient- and clinician-assessed performance status and the role of wearable activity trackers to assist in performance status assessment in advanced cancer patients	10
Contact with lung cancer patients during COVID-19: findings from Ireland and the UK from a global survey of patient experience	10
109 Developing the role of the Lung Cancer Nurse Specialist (CNS) to support wider Clinical Practice beyond traditional role boundaries	10
33 Implementation of a Lung Oncology Virtual Ward (VW) – Accelerating Responsiveness to Personalised Care Management	10
Final survival results for the LURET phase II study of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer	10
182 Lung cancer findings from two Targeted Lung Health Check programmes running simultaneously across different geographically close regions and NHS trusts	10
51 Percutaneous tissue sampling in thoracic oncology - are core biopsies bigger and better?	10
Real-world insights into patients with advanced NSCLC and MET alterations	10
Findings from a global survey of patient experience: Ireland, patient insights	9
Image guided lung biopsy	9
75 Improving Research Access for Mesothelioma Patients (IRAMP)	9
The effect of tumor size and metastatic extent on the efficacy of first line pembrolizumab monotherapy in patients with high PD-L1 expressing advanced NSCLC tumors	9
237 Assessing the effectiveness of talc pleurodesis in the prevention of malignant pleural effusions at the Royal Gwent Hospital, Newport	9
45 Optimisation of an EBUS service at a district general hospital	9
The integration of occupational therapy at the point of diagnosis in lung cancer	9
Effect of antibiotic treatment on immune checkpoint inhibitors efficacy in patients with advanced non-small cell lung cancer	9
244 Recurrence pattern post surgical resection of lung cancer with curative intent	9
203 Setting up a county-wide targeted lung health check (TLHC) programme in Dorset, run through a district general hospital (DGH)	9